Press Release

Zetagen Therapeutics, Inc. Receives Patents for Methods in Stimulating Bone Growth Using Small-Molecule

19 February 2019
  • U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
  • Latest patent issuance furthers the Company’s Global IP strategy
  • Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions

February 19, 2019– (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and orthopedic interventions, announced today that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 10208306 and the South African Patent Office issued PCT. 2017/00029 to the Company. These patents, entitled Composition and Methods to Promote Bone Formation, include claims covering the use of methods for stimulating bone growth using its novel molecular pathway, ZetaMet™ (Zeta-BC-003). ZetaMet™ (Zeta-BC-003) is a synthetic, small molecule, inductive biologic, delivered via a drug-eluting implant on an osteopromotive carrier.

“These new patent issuances are an important step forward towards our ultimate goal of obtaining the global, commercial rights for our treatments,” said Joe C. Loy, CEO of Zetagen Therapeutics, Inc. “We believe in the potential our therapies hold for patients around the world who live with debilitating metastatic bone cancers.”

The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions and osteologic interventions. Zetagen exclusively licensed its platform technology from the State University of New York in 2016.

All News

About zetagen Therapeutics

Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs.

The company's pipeline encompasses several oncological candidates targeting metastatic and primary cancers for breast, lung, brain, prostate, and sarcomas with such drugs as ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005).

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
Source: Zetagen Therapeutics, Inc.
SUNY Biotech Accelerator
841 E Fayette Street, Suite 1100
Syracuse, NY 13210
Investor Inquiries:
Zetagen Therapeutics, Inc.

Media Inquiries:
Mog & Springer Communications on Behalf of Zetagen Therapeutics, Inc.
Elizabeth Harness, Principal
Phone: +1-585-435-7379